dm+d

417440006

Articles

Human alpha1-proteinase inhibitor

29 August 2019Serine endopeptidase inhibitor
Search Articles

New Medicines

GlassiaAlpha-1 antitrypsin deficiency (AATD); inhaled therapy for emphysema

Information

Glassia
New formulation
Kamada
Kamada

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase II Clinical Trials
Yes

Category

Serine endopeptidase inhibitor
The prevalence of the genotype associated with severe AATD is estimated to be 1 in every 1,600 to 5,000 newborns. Using data from a registry (ADAPT), about 670 patients in England have AATD; about 80%have clinically significant disease which may require therapy with Respreeza. In England, this would equate to a population of 540 patients. Those who go on to develop emphysema is unknown, but is thought the majority are unaffected.[3]
Alpha-1 antitrypsin deficiency (AATD); inhaled therapy for emphysema
Inhalation

GlassiaGraft versus host disease (GvHD)

Information

Glassia
Licence extension / variation
Kamada
Kamada

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes

Category

Serine endopeptidase inhibitor
Immunosuppressed patients who receive white blood cells from another person are at risk of GVHD. The incidence of acute GVHD varies widely ranging from 10-80%, depending on risk factors [4].
Graft versus host disease (GvHD)
Intravenous